NCT00463710View on ClinicalTrials.gov

Effect of Interferon Beta-1a (Avonex®) on Changes of Non-conventional MRI Measures in Patients With MS

CompletedOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

June 30, 2005

Study Completion Date

September 30, 2006

Conditions
Multiple Sclerosis
Interventions
DRUG

Avonex® monotherapy (6.0 MIU administered i.m. each week)

Trial Locations (1)

14127

The Jacobs Neurological Institute, Buffalo

Sponsors

Collaborators (1)

Biogen
All Listed Sponsors
collaborator

Biogen

INDUSTRY

lead

State University of New York at Buffalo

OTHER